Patents by Inventor Mae Jean Miller

Mae Jean Miller has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FUNCTIONAL ROLE OF ADRENOMEDULLIN (AM) AND THE GENE RELATED PRODUCT (PAMP) IN HUMAN PATHOLOGY AND PHYSIOLOGY
    Publication number: 20100021469
    Abstract: The methods of the present invention demonstrate that adrenomedullin (AM) is expressed in human cancer cell lines of diverse origin and functions as a universal autocrine growth factor driving neoplastic proliferation. The present invention provides for AM peptides and AM antibodies useful in therapeutic, pharmacologic and physiologic compositions. The present invention additionally provides for methods of diagnosis, treatment and prevention of disease utilizing compositions comprising the AM peptides and antibodies of the present invention. The methods of the present invention also provide for experimental models for use in identifying the role of AM in pancreatic physiology. The methods pertaining to rat isolated islets have show that AM inhibits insulin secretion in a dose-dependent manner. The monoclonal antibody MoAb-G6, which neutralizes AM bioactivity, was show by the methods of the present invention to increase insulin release fivefold, an effect that was reversed by the addition of synthetic AM.
    Type: Application
    Filed: September 29, 2009
    Publication date: January 28, 2010
    Inventors: Frank Cuttitta, Alfredo Martinez, Mae Jean Miller, Edward J. Unsworth, William A. Hook, Thomas Walsh, Karen Gray, Charles Macri
  • Functional role of adrenomedullin (AM) and the gene-related product (PAMP) in human pathology and physiology
    Patent number: 7101548
    Abstract: The methods of the present invention demonstrate that adrenomedullin (AM) is expressed in human cancer cell lines of diverse origin and functions as a universal autocrine growth factor driving neoplastic proliferation. The present invention provides for AM peptides and AM antibodies useful in therapeutic, pharmacologic and physiologic compositions. The present invention additionally provides for methods of diagnosis, treatment and prevention of disease utilizing compositions comprising the AM peptides and antibodies of the present invention. The methods of the present invention also provide for experimental models for use in identifying the role of AM in pancreatic physiology. The methods pertaining to rat isolated islets have shown that AM inhibits insulin secretion in a dose-dependent manner. The monoclonal antibody MoAb-G6, which neutralizes AM bioactivity, was shown by the methods of the present invention to increase insulin release fivefold, an effect that was reversed by the addition of synthetic AM.
    Type: Grant
    Filed: August 16, 2001
    Date of Patent: September 5, 2006
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Frank Cuttitta, Alfredo Martinez, Mae Jean Miller, Edward J. Unsworth, William Hook, Thomas Walsh, Karen Gray, Charles Macri
  • Functional role of adrenomedullin (AM) and the gene-related product (PAMP) in human pathology and physiology
    Publication number: 20020055615
    Abstract: The methods of the present invention demonstrate that adrenomedullin (AM) is expressed in human cancer cell lines of diverse origin and functions as a universal autocrine growth factor driving neoplastic proliferation. The present invention provides for Tpeptides and AM antibodies useful in therapeutic, pharmacologic and physiologic compositions. The present invention additionally provides for methods of diagnosis, treatment and prevention of disease utilizing compositions comprising the AM peptides and antibodies of the present invention. The methods of the present invention also provide for experimental models for use in identifying the role of AM in pancreatic physiology. The methods pertaining to rat isolated islets have shown that AM inhibits insulin secretion in a dose-dependent manner. The monoclonal antibody MoAb-G6, which neutralizes AM bioactivity, was shown by the methods of the present invention to increase insulin release fivefold, an effect that was reversed by the addition of synthetic AM.
    Type: Application
    Filed: August 16, 2001
    Publication date: May 9, 2002
    Inventors: Frank Cuttitta, Alfredo Martinez, Mae Jean Miller, Edward J. Unsworth, William Hook, Thomas Walsh, Karen Gray, Charles Macri
  • Adrenomedullin peptides
    Patent number: 6320022
    Abstract: The methods of the present invention demonstrate that adrenomedullin (AM) is expressed in human cancer cell lines of diverse origin and functions as a universal autocrine growth factor driving neoplastic proliferation. The present invention provides for AM peptides and AM antibodies useful in therapeutic, pharmacologic and physiologic compositions. The present invention additionally provides for methods of diagnosis, treatment and prevention of disease utilizing compositions comprising the AM peptides and antibodies of the present invention. The methods of the present invention also provide for experimental models for use in identifying the role of AM in pancreatic physiology. The methods pertaining to rat isolated islets have shown that AM inhibits insulin secretion in a dose-dependent manner. The monoclonal antibody MoAb-G6, which neutralizes AM bioactivity, was shown by the methods of the present invention to increase insulin release fivefold, an effect that was reversed by the addition of synthetic AM.
    Type: Grant
    Filed: February 17, 1998
    Date of Patent: November 20, 2001
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Frank Cutitta, Alfredo Martinez, Mae Jean Miller, Edward J. Unsworth, William Hook, Thomas Walsh, Karen Gray, Charles Macri